中国卒中杂志 ›› 2023, Vol. 18 ›› Issue (01): 54-59.DOI: 10.3969/j.issn.1673-5765.2023.01.004
沈懿, 武剑
收稿日期:
2022-11-01
出版日期:
2023-01-20
发布日期:
2023-01-20
通讯作者:
武剑 wujianxuanwu@126.com
基金资助:
首都卫生发展科研专项项目(首发2020-1-2241)
北京市医院管理局临床医学发展专项(XMLX202140)
清华大学精准医学科研计划(10001020104; 10001020128)
北京市医院管理中心“创新梦工场”资助项目 (202119)
Received:
2022-11-01
Online:
2023-01-20
Published:
2023-01-20
沈懿, 武剑. 缺血性卒中二级预防降压药物的选择[J]. 中国卒中杂志, 2023, 18(01): 54-59.
SHEN Yi, WU Jian. How to Select Antihypertensive Drugs for Secondary Prevention of Stroke? [J]. Chinese Journal of Stroke, 2023, 18(01): 54-59.
[1] 王拥军,李子孝,谷鸿秋,等. 中国卒中报告2020(中文版)(1)[J]. 中国卒中杂志,2022,17(5):433-447. [2] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J]. 中华神经科杂志,2022,55(10):1071-1110. [3] 中国医师协会心血管内科医师分会,中国心衰中心联盟,《慢性心力衰竭"新四联"药物治疗临床决策路径专家共识》工作组. 慢性心力衰竭“新四联”药物治疗临床决策路径专家共识[J]. 中国循环杂志,2022,37(8):769-781. [4] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J]. 中华糖尿病杂志,2021,13(8):762-784. [5] PITT B,FILIPPATOS G,AGARWAL R,et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med,2021,385(24):2252-2263. [6] BOSCH J,LONN E,POGUE J,et al. Long-term effects of ramipril on cardiovascular events and on diabetes:results of the HOPE study extension[J]. Circulation,2005,112(9):1339-1346. [7] PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack[J]. Lancet,2001,358(9287):1033-1041. [8] KLEINDORFER D O,TOWFIGHI A,CHATURVEDI S,et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack:a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke,2021,52(7):e364-e467[2022-10-25]. https://doi.org/10.1161/STR.0000000000000375. [9] MA C,CAO J,LU X C,et al. Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI[J]. J Geriatr Cardiol,2012,9(3):252-257. [10] SCHRADER J,LÜDERS S,KULSCHEWSKI A,et al. Morbidity and mortality after stroke,eprosartan compared with nitrendipine for secondary prevention:principal results of a prospective randomized controlled study(MOSES)[J]. Stroke,2005,36(6):1218-1226. [11] BOULANGER J M,HILL M D. Morbidity and mortality after stroke—eprosartan compared with nitrendipine for secondary prevention:principal results of a prospective randomized controlled study(MOSES)[J]. Stroke,2006,37(2):335-336,338. [12] STRANDBERG T E. Secondary prevention of stroke is important:but all hypertensive drugs are not created equal?[J]. Stroke,2005,36(6):1225-1226. [13] WEI J,GALAVIZ K I,KOWALSKI A J,et al. Comparison of cardiovascular events among users of different classes of antihypertension medications:a systematic review and network meta-analysis[J/OL]. JAMA Netw Open,2020,3(2):e1921618[2022-10-25]. https://doi.org/10.1001/jamanetworkopen.2019.21618. [14] 国家卫生计生委脑卒中防治工程委员会. 中国脑卒中防治血压管理指导规范[S]. 2017. [15] CHI N F,CHUNG C P,CHENG H M,et al. 2021 Taiwan Stroke Society guidelines of blood pressure control for ischemic stroke prevention[J]. J Chin Med Assoc,2022,85(6):651-664. [16] DAWSON J,BÉJOT Y,CHRISTENSEN L M,et al. European Stroke Organisation(ESO)guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack[J/OL]. Eur Stroke J,2022,7(3):Ⅰ-Ⅱ[2022-10-25]. https://doi.org/10.1177/23969873221100032. [17] 国家卫生计生委脑卒中防治工程委员会. 中国脑卒中防治指导规范(2021年版)[S]. 2021. [18] JAMERSON K,WEBER M A,BAKRIS G L,et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients[J]. N Engl J Med,2008,359(23):2417-2428. [19] OGIHARA T,SARUTA T,RAKUGI H,et al. Combination therapy of hypertension in the elderly:a subgroup analysis of the combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial[J]. Hypertens Res,2015,38(1):89-96. [20] MATSUZAKI M,OGIHARA T,UMEMOTO S,et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension:a randomized controlled trial[J]. J Hypertens,2011,29(8):1649-1659. [21] DUPUIS F,ATKINSON J,LIMIÑANA P,et al. Captopril improves cerebrovascular structure and function in old hypertensive rats[J]. Br J Pharmacol,2005,144(3):349-356. [22] HILLMEISTER P,NAGORKA S,GATZKE N,et al. Angiotensin-converting enzyme inhibitors stimulate cerebral arteriogenesis[J/OL]. Acta Physiol(Oxf),2022,234(2):e13732[2022-10-25]. https://doi.org/10.1111/apha.13732. [23] RIGSBY C S,ERGUL A,PORTIK DOBOS V,et al. Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension[J]. Am J Hypertens,2011,24(6):708-715. [24] PANAHPOUR H,TERPOLILLI N A,SCHAFFERT D,et al. Central application of aliskiren,a renin inhibitor,improves outcome after experimental stroke independent of its blood pressure lowering effect[J/OL]. Front Neurol,2019,10:942[2022-10-25]. https://doi.org/10.3389/fneur.2019.00942. [25] MIAO J Y,WANG L N,ZHANG X J,et al. Protective effect of aliskiren in experimental ischemic stroke:up-regulated p-PI3K,p-AKT,Bcl-2 expression,attenuated bax expression[J]. Neurochem Res,2016,41(9):2300-2310. [26] SCHMERBACH K,PFAB T,ZHAO Y,et al. Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes[J/OL]. PLoS One,2010,5(11):e15052[2022-10-25]. https://doi.org/10.1371/journal.pone.0015052. [27] RUBATTU S,FORTE M,MARCHITTI S,et al. Molecular implications of natriuretic peptides in the protection from hypertension and target organ damage development[J/OL]. Int J Mol Sci,2019,20(4):798[2022-10-25]. https://doi.org/10.3390/ijms20040798. [28] RUBATTU S,COTUGNO M,FORTE M,et al. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat[J]. J Hypertens,2018,36(9):1902-1914. [29] 中国医疗保健国际交流促进会高血压分会,北京脑血管病防治协会. 急性缺血性卒中合并心脏病患者血压管理专家共识[J]. 中华内科杂志,2021,60(4):306-313. [30] 北京高血压防治协会,中国卒中学会高血压预防与管理分会,中国老年保健协会养老与健康专业委员会,等. 基层冠心病与缺血性脑卒中共患管理专家共识2022[J]. 中国心血管病研究,2022,20(9):772-793. [31] 中国中医药研究促进会中西医结合心血管病预防与康复专业委员会高血压专家委员会,北京高血压防治协会,中国高血压联盟,等. 特殊类型高血压临床诊治要点专家建议[J]. 中国全科医学,2020,23(10):1202-1228. [32] DAGRES N,CHAO T F,FENELON G,et al. European Heart Rhythm Association(EHRA)/Heart Rhythm Society(HRS)/Asia Pacific Heart Rhythm Society(APHRS)/Latin American Heart Rhythm Society(LAHRS)expert consensus on arrhythmias and cognitive function:what is the best practice?[J]. Europace,2018,20(9):1399-1421. [33] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国脑小血管病诊治指南2020[J]. 中华神经科杂志,2022,55(8):807-818. [34] 段雅鑫,裴晗蕾,成斯琪,等. 血压变异性与脑小血管病[J]. 国际脑血管病杂志,2020,28(12):926-932. [35] 李铁梅. 血压变异性与脑小血管病:人群队列的系统回顾和荟萃分析[J]. 中华医学杂志,2020,100(43):3430. [36] GOLDSTEIN E D,WOLCOTT Z,GARG G,et al. Effect of antihypertensives by class on cerebral small vessel disease:a post hoc analysis of SPRINT-MIND[J]. Stroke,2022,53(8):2435-2440. [37] DING J,DAVIS-PLOURDE K L,SEDAGHAT S,et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease:a meta-analysis of individual participant data from prospective cohort studies[J]. Lancet Neurol,2020,19(1):61-70. [38] 中国医师协会睡眠医学专业委员会. 成人阻塞性睡眠呼吸暂停多学科诊疗指南[J]. 中华医学杂志,2018,98(24):1902-1914. [39] SEILER A,CAMILO M,KOROSTOVTSEVA L,et al. Prevalence of sleep-disordered breathing after stroke and TIA:a meta-analysis[J/OL]. Neurology,2019,92(7):e648-e654[2022-10-25]. https://doi.org/10.1212/WNL.0000000000006904. [40] GBD 2016 Neurology Collaborators. Global,regional,and national burden of neurological disorders,1990-2016:a systematic analysis for the global burden of disease study 2016[J]. Lancet Neurol,2019,18(5):459-480. [41] BAILLIEUL S,DEKKERS M,BRILL A K,et al. Sleep apnoea and ischaemic stroke:current knowledge and future directions[J]. Lancet Neurol,2022,21(1):78-88. [42] 嵇朋,屈雪萍,江利敏,等. 阻塞型睡眠呼吸暂停低通气综合征对急性缺血性卒中患者脑血管反应性的影响[J]. 中国卒中杂志,2021,16(10):1034-1038. [43] MCEVOY R D,ANTIC N A,HEELEY E,et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea[J]. N Engl J Med,2016,375(10):919-931. [44] 周正宏,于逢春,孟晓梅,等. 阻塞性睡眠呼吸暂停低通气综合征与非心源性缺血性卒中复发关系探讨[J]. 中国卒中杂志,2013,8(9):697-702. [45] 李建章,张杰文,刘恒方.慢性脑缺血临床诊治专家共识[J].中国实用神经疾病杂志,2022,25(6):661-667. |
[1] | 熊云云, 霍晓川, 贾白雪, 濮月华, 李光硕, 王利圆, 程丝, 郝曼均, 王拥军. 卒中:回眸2022[J]. 中国卒中杂志, 2023, 18(01): 1-16. |
[2] | 宋晓微, 桑振华, 侯朵朵, 陈文文, 张红亮, 郑卓肇, 赵锡海, 李睿, 武剑. 血压昼夜节律变化与颅内动脉粥样硬化斑块特征的相关性研究[J]. 中国卒中杂志, 2023, 18(01): 61-67. |
[3] | 吴雅婷, 魏宸铭, 武剑. 卒中患者血压水平与卒中后认知障碍关系的研究进展[J]. 中国卒中杂志, 2023, 18(01): 68-75. |
[4] | 宋彦丽, 林杰, 武一平, 李晓晶, 刘改芬, 夏文静, 张玉英, 张晓林, 吕晨冉, 周红, 李凯, 薛斌, 陈玲玲, 张忠波, 彭晓. 邯郸市居民心脑血管病危险因素的流行现状及高血压知晓率、治疗率和控制率的影响因素研究 [J]. 中国卒中杂志, 2022, 17(12): 1360-1365. |
[5] | 吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371. |
[6] | 郑占军, 赵性泉. 脑小血管病影像学标志物与自发性高血压脑出血的相关性研究进展[J]. 中国卒中杂志, 2022, 17(12): 1396-1402. |
[7] | 伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170. |
[8] | 王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177. |
[9] | 崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188. |
[10] | 刘光亮, 韩凯月, 苏文龙, 张皓. 不同强度有氧踏车训练对不同病程缺血性卒中患者运动和心肺适能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1203-1208. |
[11] | 杨红娜, 冀瑞俊, 于凯, 何艳, 徐丽华, 王拥军. 缺血性脑血管病二级预防药物依从性及其影响因素研究 [J]. 中国卒中杂志, 2022, 17(11): 1227-1232. |
[12] | 徐莹鑫, 张爽, 周晓梅, 袁景林, 赵留庄, 杨海华. 非狭窄性颈动脉斑块与前循环不明原因栓塞性卒中的相关性研究 [J]. 中国卒中杂志, 2022, 17(11): 1233-1237. |
[13] | 程实, 李静, 郭军平, 胡爱香, 于鑫玮, 韩玮, 梁瑛, 张越巍, 冀瑞俊. 急性卒中患者住院期间感染的临床特征及危险因素分析[J]. 中国卒中杂志, 2022, 17(10): 1065-1070. |
[14] | 向薇, 徐璐瑶, 张曼曼, 魏红春, 梁志刚. 缺血性卒中急性期磁敏感加权成像不对称突出静脉征的发生率及影响因素分析[J]. 中国卒中杂志, 2022, 17(10): 1097-1102. |
[15] | 赵永瑞, 刘展会. 弥散张量成像在缺血性卒中患者运动功能预后评估中的研究进展[J]. 中国卒中杂志, 2022, 17(10): 1114-1119. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||